Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study.


Journal

Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857

Informations de publication

Date de publication:
05 2020
Historique:
received: 16 08 2019
revised: 11 11 2019
accepted: 18 11 2019
pubmed: 26 11 2019
medline: 22 6 2021
entrez: 26 11 2019
Statut: ppublish

Résumé

Hepatitis C virus (HCV) genotype (GT) 4 infection is prevalent in sub-Saharan Africa and the Middle East, particularly in Egypt. This study evaluated the safety and efficacy of elbasvir/grazoprevir administered for 8 and 12 weeks in participants with HCV GT4 infection. In this partially randomized, open-label multicentre study conducted in France (NCT03111108; Protocol MK5172-096), treatment-naive participants with GT4 infection and F0-F2 fibrosis were randomized 2:1 to elbasvir (50 mg)/grazoprevir (100 mg) for 8 or 12 weeks. Treatment-naive participants with F3-F4 fibrosis and all treatment-experienced participants (F0-F4) were assigned to elbasvir/grazoprevir for 12 weeks. The primary endpoint was sustained virologic response (SVR) 12 weeks after the end of therapy. One hundred and seventeen participants were enrolled. Among treatment-naive participants with F0-F2 fibrosis, SVR was achieved by 94% (50/53) and 96% (26/27) of those receiving elbasvir/grazoprevir for 8 or 12 weeks, respectively, and four participants relapsed. In the 12-week arm, 95% (35/37) achieved SVR and two participants relapsed. NS5A resistance-associated substitutions were present at baseline and virologic failure in five of the participants with relapse. Drug-related adverse events occurred in 42% (n = 22) and 50% (n = 32) of participants receiving 8 and 12 weeks of treatment, respectively. No participant discontinued treatment owing to an adverse event. These data confirm the efficacy of elbasvir/grazoprevir administered for 12 weeks in treatment-experienced individuals with HCV GT4 infection and those with advanced fibrosis. Treatment-naive individuals with mild fibrosis can be treated effectively with an 8-week regimen.

Sections du résumé

BACKGROUND & AIMS
Hepatitis C virus (HCV) genotype (GT) 4 infection is prevalent in sub-Saharan Africa and the Middle East, particularly in Egypt. This study evaluated the safety and efficacy of elbasvir/grazoprevir administered for 8 and 12 weeks in participants with HCV GT4 infection.
METHODS
In this partially randomized, open-label multicentre study conducted in France (NCT03111108; Protocol MK5172-096), treatment-naive participants with GT4 infection and F0-F2 fibrosis were randomized 2:1 to elbasvir (50 mg)/grazoprevir (100 mg) for 8 or 12 weeks. Treatment-naive participants with F3-F4 fibrosis and all treatment-experienced participants (F0-F4) were assigned to elbasvir/grazoprevir for 12 weeks. The primary endpoint was sustained virologic response (SVR) 12 weeks after the end of therapy.
RESULTS
One hundred and seventeen participants were enrolled. Among treatment-naive participants with F0-F2 fibrosis, SVR was achieved by 94% (50/53) and 96% (26/27) of those receiving elbasvir/grazoprevir for 8 or 12 weeks, respectively, and four participants relapsed. In the 12-week arm, 95% (35/37) achieved SVR and two participants relapsed. NS5A resistance-associated substitutions were present at baseline and virologic failure in five of the participants with relapse. Drug-related adverse events occurred in 42% (n = 22) and 50% (n = 32) of participants receiving 8 and 12 weeks of treatment, respectively. No participant discontinued treatment owing to an adverse event.
CONCLUSION
These data confirm the efficacy of elbasvir/grazoprevir administered for 12 weeks in treatment-experienced individuals with HCV GT4 infection and those with advanced fibrosis. Treatment-naive individuals with mild fibrosis can be treated effectively with an 8-week regimen.

Identifiants

pubmed: 31765046
doi: 10.1111/liv.14313
doi:

Substances chimiques

Amides 0
Antiviral Agents 0
Benzofurans 0
Carbamates 0
Cyclopropanes 0
Imidazoles 0
Quinoxalines 0
Sulfonamides 0
grazoprevir 4O2AB118LA
elbasvir 632L571YDK

Banques de données

ClinicalTrials.gov
['NCT03111108']

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1042-1051

Informations de copyright

© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1 Suppl):S45-S57.
Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161-176.
Asselah T, Hassanein T, Waked I, Mansouri A, Dusheiko G, Gane E. Eliminating hepatitis C within low-income countries - the need to cure genotypes 4, 5, 6. J Hepatol. 2018;68(4):814-826.
Fourati S, Rodriguez C, Hézode C, et al. Frequent antiviral treatment failures in patients infected with hepatitis C virus genotype 4, subtype 4r. Hepatology. 2019;69(2):513-523.
Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163(1):1-13.
Kwo P, Gane EJ, Peng C-Y, et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology. 2017;152(1):164-175.
Jacobson IM, Lawitz E, Kwo PY, et al. Safety and efficacy of elbasvir/grazoprevir in patients with hepatitis C virus infection and compensated cirrhosis: an integrated analysis. Gastroenterology. 2017;152(6):1372-1382.
Hézode C, Colombo M, Bourlière M, et al. Elbasvir/grazoprevir for patients with hepatitis C virus infection and inherited blood disorders: a phase III study. Hepatology. 2017;66(3):736-745.
Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386(10003):1537-1545.
Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2(8):e319-e327.
Zeuzem S, Serfaty L, Vierling J, et al. The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. J Gastroenterol. 2018;53(5):679-688.
Asselah T, Reesink H, Gerstoft J, et al. Efficacy of elbasvir and grazoprevir in participants with hepatitis c virus genotype 4 infection: a pooled analysis. Liver Int. 2018;38(9):1583-1591.
Zepatier [prescribing information]. Whitehouse Station, NJ, USA: Merck Sharp & Dohme Corp.; 2018.
European Medicines Agency. EPAR summary for the public. Zepatier Elbasvir/Grazoprevir. 2016. https://www.ema.europa.eu/en/documents/overview/zepatier-epar-summary-public_en.pdf. Accessed June 24, 2019.
Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343-350.
Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005;41(1):48-54.
Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48(5):835-847.

Auteurs

Tarik Asselah (T)

Department of Hepatology and Gastroenterology, University Paris Diderot, Sorbonne Paris Cité, CRI, UMR 1149 INSERM, Paris, France.
Department of Hepatology, AP-HP Hôpital Beaujon, Clichy, France.

Stanislas Pol (S)

Department of Hepatology, APHP Hôpital Cochin/Université Paris Descartes/INSERM U1223, Institut Pasteur, Paris, France.

Christophe Hezode (C)

Department of Hepatology, Henri Mondor Hospital, APHP, University of Paris-Est, INSERM U955, Créteil, France.

Veronique Loustaud-Ratti (V)

Department of Hepatology and Gastroenterology, CHU de Limoges, U850 INSERM, Université Limoges, Limoges, France.

Vincent Leroy (V)

CHU de Grenoble Alpes, Grenoble, France.

Si Nafa Si Ahmed (SNS)

Department of Hepatology and Gastroenterology, Pȏle de Recherche Clinique, Hôpital Saint Joseph, Marseille, France.

Violaine Ozenne (V)

Department of Hepatology and Gastroenterology, Hôpital Saint Antoine, Paris, France.

Jean-Pierre Bronowicki (JP)

Department of Hepatology and Gastroenterology, CHU de Nancy, Nancy, France.

Dominique Larrey (D)

Department of Hepatology, Hôpital Saint Eloi, Ecole de Médecine de Montpellier, Montpellier, France.

Albert Tran (A)

Department of Gastroenterology, Université Côte d'Azur, Nice, France.
Centre Digestif, CHU de Nice, Nice, France.
INSERM, U1065, C3M, Team 8, Nice, France.

Laurent Alric (L)

Department of Internal Medicine/Gastroenterology, CHU de Toulouse, Toulouse, France.

Eric Nguyen-Khac (E)

Department of Hepatology and Gastroenterology, CHU de Amiens, Amiens, France.

Michael N Robertson (MN)

Department of Infectious Diseases, Merck & Co., Inc., Kenilworth, NJ, USA.

George J Hanna (GJ)

Department of Infectious Diseases, Merck & Co., Inc., Kenilworth, NJ, USA.

Deborah Brown (D)

Department of Infectious Diseases, Merck & Co., Inc., Kenilworth, NJ, USA.

Ernest Asante-Appiah (E)

Department of Infectious Diseases, Merck & Co., Inc., Kenilworth, NJ, USA.

Feng-Hsiu Su (FH)

Department of Infectious Diseases, Merck & Co., Inc., Kenilworth, NJ, USA.

Peggy Hwang (P)

Department of Infectious Diseases, Merck & Co., Inc., Kenilworth, NJ, USA.

Jessie Durrand Hall (JD)

Department of Infectious Diseases, Merck & Co., Inc., Kenilworth, NJ, USA.

Amir Guidoum (A)

Department of Infectious Diseases, Merck & Co., Inc., Kenilworth, NJ, USA.

Karin Hagen (K)

Department of Infectious Diseases, Merck & Co., Inc., Kenilworth, NJ, USA.

Barbara A Haber (BA)

Department of Infectious Diseases, Merck & Co., Inc., Kenilworth, NJ, USA.

Rohit Talwani (R)

Department of Infectious Diseases, Merck & Co., Inc., Kenilworth, NJ, USA.

Lawrence Serfaty (L)

Department of Hepatology, Hôpital de Hautepierre, Universitaires de Strasbourg, Strasbourg, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH